Current clinical evidence suggests that the presence of anti-TRIM21 antibodies is associated with an increased incidence of concomitant ILD in SjS, SSc, and IIM, with a higher probability of ILD occurring and being more severe, usually predicting poorer outcomes and survival. This evidence concerns the gene TRIM21 and Schwartz-Jampel syndrome.